Tags : Trazimera

Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer

Vartika Singh March 12, 2019

Shots: The approval is based on REFLECTIONS B327-02 study assessing Trazimera in 500 patients with HER2 overexpressing breast cancer & m- gastric/GEJ adenocarcinoma across 20 countries REFLECTIONS B327-02 study demonstrated […]readmore

Biosimilars Pharma

Pfizer receives EU approval for Trazimera(Trastuzumab), the First Oncology Biosimilar

Vartika Singh July 31, 2018

Shots: Trazimera is a biosimilar of Herceptin indicated for treatment of HER2 overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma The EC approval is based on the data […]readmore

Tags : Trazimera

Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer

Pfizer receives EU approval for Trazimera(Trastuzumab), the First Oncology Biosimilar

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Trazimera

Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer

Pfizer receives EU approval for Trazimera(Trastuzumab), the First Oncology Biosimilar

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company